摘要
目的建立HPLC法同时检测人血浆中异烟肼及其代谢产物乙酰异烟肼的浓度。方法采用HPLC法,血浆用20%三氯乙酸沉淀蛋白后,旋涡混匀1 min,离心10 min,取上清液进行分析,以外标法定量。色谱柱为SinoChrom ODS-BP(250 mm×4.6 mmm,5μm),保护柱为Hypersil ODS(C18),流动相为乙腈-0.05 mol·mL^(-1)磷酸二氢钾溶液(含0.04%三乙胺)(3:97),流速为1.0mL·min^(-1),柱温为30.0℃,检测波长为265 nm。结果异烟肼和乙酰异烟肼质量浓度在0.25~20.00 mg·L^(-1)内线性关系良好,回归方程分别为y=1 113.0 x-150.9(r=0.999 8)和y=529.8x-131.9(r=0.999 7),定量下限均为0.25 mg·L^(-1);异烟肼的回收率为100%~104%,乙酰异烟肼为90%~106%;低、中、高浓度的日内、日间精密度良好(RSD均<15%)。结论本方法专属性好,样品处理简单,适用于人血浆中异烟肼及乙酰异烟肼的含量测定。
AIM To establish an HPLC method for the determination of isoniazid(INH) and acetylisoniazid (Ac- INH) in human plasma. METHODS By HPLC method, serum protein was precipitated with 20% trichloroacetic acid, mixed vortically for 1 min, then centrifuged for 10 min, and the supernatant was taken for analysis. Separation was performed on a SinoChrom ODS-BP column with a Hypersil ODS(C18) guard column. The mobile phase was acetontrile - 0.05 mol· mL^- 1 KH2PO4(0.04% triethylamine) with the ratio of 3:97. The column temperature was 30.0℃. The flow rate was 1.0 mL· min^- 1 and the detection wavelength was 265 nm. RESULTS Both calibration curves had good linearity in the range of 0.25- 20.00 mg· L^-1. The calibration curves of isoniazid and acetylisoniazid were y = 1 113.0 x- 150.9( r = 0.999 8)and y = 529.8x - 131.9( r = 0.999 7) respectively. The limit of quantification was 0.25 mg·L^- 1 for both isoniazid and acetylisoniazid. The recovery of isoniazid was in the range of 100% - 104%, and that of acetylisoniazid was in the range of 90% - 106%. The intra-day and inter-day RSD for assaying the sample containing three concentrations of isoniazid and acetylisoniazid were all lower than 15%. CONCLUSION The method is sensitive, simple and quick. It is suitable for the analysis of isoniazid and acetylisoniazid in human plasma.
作者
杨金招
夏梦华
王淑君
陈连国
林玉仙
熊建华
YANG Jinzhao XIA Menghua WANG Sbujun CHEN Lianguo LIN Yuxian XIONG Jianhua(Department of Phamacy, Wenzhou People's Hospital, Wenzhou 325000, China School of Pharmacy, Fujian Medical University, Fuzhou 350108, China)
出处
《中国临床药学杂志》
CAS
2016年第6期349-353,共5页
Chinese Journal of Clinical Pharmacy
基金
温州市医药卫生科研项目(编号2013A05)